obesity

News

Lilly launches telehealth option for obesity and other drugs

Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel that could shake up

News

Novo Nordisk’s Flagship alliance bears obesity, MASH fruit

Novo Nordisk has reaped the first harvest from its wide-ranging alliance with life sciences investor Flagship Pioneering, buying rights to two programmes from the VC’s por

R&D

The race for obesity drug assets heats up

The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident.

News

AI specialist Fauna grabs $494m Lilly obesity alliance

A US biotech that is trying to find new avenues for treating human diseases by studying the genomics of animal species, Fauna Bio, has agreed a deal with Eli Lilly focusin

Market Access

Nine for 2024, Pt 1: From fragility to resilience

This year was a year of significant new beginnings for pharma and healthcare, yet, it was still impacted by the long-term fallouts of the pandemic.

News

Pfizer drops twice-daily obesity therapy due to side effects

Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage

Lilly launches telehealth option for obesity and other drugs

Novo Nordisk’s Flagship alliance bears obesity, MASH fruit

The race for obesity drug assets heats up

AI specialist Fauna grabs $494m Lilly obesity alliance

Nine for 2024, Pt 1: From fragility to resilience

Pfizer drops twice-daily obesity therapy due to side effects

J&J scores EU approval for Tecvayli combo in second line

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks